BioMarin Pharmaceutical Inc.
BMRN
$53.82
-$0.49-0.90%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.08% | 15.92% | 14.84% | 15.65% | 28.28% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.08% | 15.92% | 14.84% | 15.65% | 28.28% |
| Cost of Revenue | -25.67% | -0.91% | -6.02% | -1.30% | 47.18% |
| Gross Profit | 14.13% | 29.22% | 36.46% | 20.24% | 22.94% |
| SG&A Expenses | 5.89% | -11.69% | -8.76% | -1.06% | 17.48% |
| Depreciation & Amortization | -3.23% | -66.11% | -66.10% | -36.66% | -68.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.23% | -7.28% | -8.61% | -6.92% | 14.71% |
| Operating Income | -141.00% | 129.87% | 185.35% | 527.75% | 273.11% |
| Income Before Tax | -119.58% | 125.43% | 125.58% | 777.73% | 222.64% |
| Income Tax Expenses | -84.42% | 129.69% | 210.35% | 4,364.89% | 2,096.82% |
| Earnings from Continuing Operations | -128.98% | 124.43% | 109.43% | 513.22% | 162.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.98% | 124.43% | 109.43% | 513.22% | 162.72% |
| EBIT | -141.00% | 129.87% | 185.35% | 527.75% | 273.11% |
| EBITDA | -121.22% | 101.10% | 132.45% | 259.90% | 136.43% |
| EPS Basic | -128.74% | 122.35% | 107.14% | 506.11% | 159.72% |
| Normalized Basic EPS | -119.42% | 123.32% | 146.43% | 817.78% | 218.79% |
| EPS Diluted | -129.25% | 124.28% | 108.02% | 644.69% | 160.67% |
| Normalized Diluted EPS | -120.11% | 129.33% | 152.72% | 805.71% | 212.92% |
| Average Basic Shares Outstanding | 0.84% | 0.94% | 1.11% | 1.17% | 1.17% |
| Average Diluted Shares Outstanding | -2.59% | -1.70% | -1.40% | 2.47% | 3.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |